EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. - Wikidata - wikimedia - TriplyDB

EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

http://www.wikidata.org/entity/Q38119843

about

Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event Alterations in Memory and Impact on Academic Outcomes in Children Following Allogeneic Hematopoietic Cell Transplantation.Immunotherapy for viral and fungal infections.The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma.Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis.Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study.Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.Epstein-Barr Virus+ Smooth Muscle Tumors as Manifestation of Primary Immunodeficiency Disorders.

P2860

Q26822550-2AF61CD2-C43E-4139-8464-752378B4AD9D Q29248394-D40799D2-6F64-4ACA-814B-CE367C9FCFB3 Q33619215-205FA500-83F5-40C5-AC78-BBE99970F5B3 Q34991001-F62B3387-B122-433D-AD2A-883FB47438F7 Q36519976-32774E1A-8C8B-4547-AA39-3A5DB80C4447 Q38384715-A8357021-B8C4-4101-A02F-23FF0F1AB177 Q38514499-DCE931AC-543C-4C3B-9D7F-049DA594B494 Q38956462-195F5761-365E-48A0-BA1C-0681B3215702 Q39036600-8851169A-F63F-4559-BB64-80E7F8694CB7 Q40106713-7745F0D8-A5C0-47DA-809C-115B429998EE Q40519555-FE5AF96C-6EA4-4DEA-99B7-7697C7EEB6C5 Q41602911-81BA722D-2C8D-46AB-BB13-FCDC135C9E0A Q41623045-7C22515B-3407-4B1D-BFE8-D3B0EE441BC7 Q42051829-CE5FCC72-8B3E-4B61-ABE1-5C2CC3B8876F Q45347053-7A684477-42B5-4371-96E3-BF76F7832257 Q52691571-2A799BF3-3BC6-4EBF-A229-26FF7D06206E Q54256451-51854342-8541-48F0-B45D-E5D50B43E6E6

P2860

EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

http://www.wikidata.org/entity/Q38119843

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

EBV-induced post transplant ly ...... n allogeneic hematopoetic SCT.

@en

type

label

EBV-induced post transplant ly ...... n allogeneic hematopoetic SCT.

@en

prefLabel

EBV-induced post transplant ly ...... n allogeneic hematopoetic SCT.

@en

P1433

Q38119843-712435E3-6212-476D-95FD-A5219F98E193

P1476

Q38119843-38DF24A4-5038-4E80-8430-EB57369987ED

P2093

Q38119843-5B319ED7-974C-4C1F-B1A4-3A5C6940E562

Q38119843-AD21558D-93E6-4139-88E5-A29C121842B7

Q38119843-B087CC43-E947-4DA7-AF87-DD3D517F1FA4

P2860

Q38119843-03262709-FD90-426B-AE58-A71350CE056A

Q38119843-11C4C7B4-A810-47E7-8995-1529900A6A4D

Q38119843-19DDC817-A95F-49FF-AA32-C06A67476C65

Q38119843-27326AED-541E-496E-8E30-51D8A4EA11DF

Q38119843-28DB4073-F4AF-47F1-9907-5F49880A0DE0

Q38119843-2D16811C-E8EA-4C1C-BE61-8C100CC806CB

Q38119843-33A92039-F91C-46E9-96B9-81CE06664ECF

Q38119843-33E74EA0-9487-413D-A013-E10E1C674723

Q38119843-3BEDF7BA-6FC1-4E0B-9F37-9FBA3C4867E3

Q38119843-4E35D5F0-B777-45DB-AA00-8295EE2676B9

P2888

Q38119843-2E292ADA-CB46-49C4-A850-22116345395B

P304

Q38119843-E20B0418-0EA6-429F-86C8-9CFB55D87EAA

P31

Q38119843-74E0E962-D4F0-40AE-B41C-F6B37464F9ED

P356

Q38119843-EA6BEF85-55E2-4D65-BA2F-6D84D4CEF7A4

P407

Q38119843-D5A8F3DB-830B-47FC-9B62-C8669DD37609

P433

Q38119843-145064AC-9155-48FF-A9E4-C4AB147B7305

P478

Q38119843-51E56B53-F17F-476B-992C-E291C8A4E7EA

P50

Q38119843-66794C30-E4F4-4A93-B8CB-936088D87309

P577

Q38119843-6245B52C-EDB2-4C7C-905A-74C33B39EE4F

P5875

Q38119843-0BC1F3E0-5B65-48A7-AF3F-3D00930636BC

P6179

Q38119843-A4B54B55-8E5A-466C-93ED-A9F7C033EE93

P698

Q38119843-41DBE082-807C-4450-922E-62071A537DDD

P356

P1433

Bone Marrow Transplantation

P1476

EBV-induced post transplant ly ...... in allogeneic hematopoetic SCT

@en

P2093

H Einsele

http://www.w3.org/2001/XMLSchema#string

L Rasche

http://www.w3.org/2001/XMLSchema#string

M Kapp

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation

Epstein-Barr virus infection.

Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.

Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.

Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies

P2888

P304

163-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2013.96

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247157153

http://www.w3.org/2001/XMLSchema#string

P6179

1027644592

http://www.w3.org/2001/XMLSchema#string

P698

23832092

http://www.w3.org/2001/XMLSchema#string